Document is current
Any future updates will be listed below
-
Authors
Wang, Tingting https://orcid.org/0000-0002-9100-3447
Jepsen, Jens Richardt Møllegaard
Vinding, Rebecca
Brustad, Nicklas https://orcid.org/0000-0001-6383-8845
Chen, Liang https://orcid.org/0000-0003-2269-6849
Hernández-Lorca, María https://orcid.org/0000-0002-0923-7173
Ali, Mina
Rosenberg, Julie Bøjstrup
Mohammadzadeh, Parisa
Widdowson, Michael https://orcid.org/0000-0001-9715-568X
Ebrahimi, Parvaneh https://orcid.org/0000-0002-9194-2073
Rasmussen, Morten A. https://orcid.org/0000-0001-7431-5206
Thorsen, Jonathan https://orcid.org/0000-0003-0200-0461
Bønnelykke, Klaus https://orcid.org/0000-0003-2003-1018
Ebdrup, Bjørn H. https://orcid.org/0000-0002-2590-5055
Chawes, Bo https://orcid.org/0000-0001-6846-6243
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (946228)
Lundbeckfonden (R269-2017-5)
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 18 December 2025
First Online: 8 January 2026
Competing interests
: B.H.E. is part of the Advisory Board of Boehringer Ingelheim, Lundbeck Pharma A/S; and has received lecture fees from Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, and Lundbeck Pharma A/S. J.T. has received a lecture fee from AstraZeneca. The remaining authors declare no conflicts of interest, whether potential, perceived, or actual, pertaining to the content of this manuscript.
